Clinical trial
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating…
NCT00425360 · Royal Liverpool University Hospital, Other · Completed
Key facts
| NCT number | NCT00425360 |
|---|---|
| Title | Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer |
| Official title | A Prospective, Phase III, Controlled, Multicentre, Randomised Clinical Trial Comparing Combination Gemcitabine and Capecitabine Therapy With Concurrent and Sequential Chemoimmunotherapy Using a Telomerase Vaccine in Locally Advanced and Metastatic Pancreatic Cancer [TELOVAC] |
| Lead sponsor | Royal Liverpool University Hospital, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Biological, Drug |
| Interventions | sargramostim, telomerase peptide vaccine GV1001, capecitabine, gemcitabine hydrochloride |
| Enrollment | 1,110 |
| Start date | Sep 1, 2006 |
| Completion | Mar 1, 2013 |
| First posted | Jan 23, 2007 |
| Last update posted | Aug 26, 2013 |
| Countries | United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: